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In the present study, a new analytical methodology was developed enabling the 23 
enantiomeric determination of N-derivatized di- and tri-peptides in dietary 24 
supplements using chiral micro-LC on a monolithic column consisting of 25 
poly(O-9-[2-(methacryloyloxy)-ethylcarbamoyl]-10,11-dihydroquinidine-co-2-hydrox26 
yethyl methacrylate-co-ethylene dimethacrylate) (poly(MQD-co-HEMA-co-EDMA)). 27 
After optimization of the mobile phase conditions, a baseline resolution of the 28 
stereoisomers of 24 out of 53 N-derivatized di- and tri-peptides was obtained. 29 
3,5-Dinitrobenzoyl- and 3,5-dichlorobenzoyl-peptide stereoisomers were separated 30 
with exceptionally high selectivity and resolution. The monolithic column was then 31 
applied to the quantitative analysis of L-carnosine and its enantiomeric impurity in 32 
three different commercial dietary supplements. Method validation demonstrated 33 
satisfactory results in terms of linearity, precision, selectivity, accuracy and limits of 34 
detection and quantification. The determined amounts of L-carnosine in commercial 35 
formulations were in agreement with the labeled content for all analyzed samples, and 36 
the enantiomeric impurity was found to be below the limit of detection (LOD), 37 
showing the potential of the poly(MQD-co-HEMA-co-EDMA) monolithic column as 38 
a reliable tool for the quality control of L-carnosine in dietary supplements by 39 
micro-LC.  40 
Keywords: carnosine / dietary supplements / enantioseparation / quinidine-based 41 
monolithic column / small peptides 42 
43 



























1. Introduction  44 
The stereochemistry of small peptides (di- and tripeptides) can profoundly influence 45 
their biological and pharmacological activities. For example, L-carnosine 46 
(β-alanyl-L-histidine) is widely distributed in mammalian tissues [1-2] and exhibits 47 
numerous biochemical properties including pH buffering [2-3], antioxidant capacity 48 
[3-4], inhibition of forming advanced glycoxidation and lipoxidation end-products [3], 49 
etc. On the contrary, its optical antipode D-carnosine cannot be hydrolyzed by 50 
carnosinases (a specific serum dipeptidase that rapidly hydrolyzes L-carnosine in 51 
vivo), making it possible to cross the blood-brain barrier and maintain the same 52 
radical-quenching activity as L-carnosine in vitro [5-6]. Hence, investigations of the 53 
stereochemical composition of small peptides are an important aspect in the field of 54 
peptide analysis [7-12]. To the best of our knowledge, most reports describing studies 55 
of the discrimination of small peptide stereoisomers have usually focused on the 56 
separation of either enantiomers or diastereomers, while papers dealing with both 57 
kinds of stereoisomers are limited [7-13]. This could be related to an obvious lack of 58 
appropriate functionalities to interact with the chiral selectors (CSs) and the 59 
complexity of the stereochemical composition of small peptides [11,13]. In order to 60 
enhance detection sensitivity and improve the intermolecular interaction between 61 
small peptides and CSs, additional interaction sites could be introduced through the 62 
derivatization of amino groups, using reagents such as 2,4-dinitrophenyl (DNP) 63 
fluoride, 3,5-dinitrobenzoyl (3,5-DNB), 9-fluorenylmethoxycarbonyl (FMOC), 64 
3,5-dinitrobenzyloxycarbonyl (3,5-DNZ) or carbazole-9-carbonyl (CC) chlorides, etc 65 
[14]. Furthermore, a wide array of analytical techniques and methods were developed 66 
for the determination of small peptide stereochemical composition [11].  67 
High-performance liquid chromatography (HPLC) is the most commonly employed 68 













separation technique for analyzing the stereochemical composition of small peptides 69 
[11,13,14], besides capillary electrophoresis (CE). In previous studies, different chiral 70 
stationary phases (CSPs) have been evaluated for the separation of all stereoisomers 71 
of small peptides by HPLC, such as those containing crown ethers [15-17], 72 
macrocylic antibiotics [18-19], cinchona alkaloids [13-14] or cyclodextrins [20-21] as 73 
chiral selectors. In particular, cinchona alkaloid based CSPs have received great 74 
attention due to their excellent stereoselectivity towards N-derivatized small peptides 75 
[13-14]. Therefore, it is of high interest to systemically evaluate their enantio- and 76 
diastereoselectivity toward a wide range of N-derivatized small peptides since only a 77 
few peptide stereoisomers have been tested with these CSPs in HPLC [13-14,22-26], 78 
capillary electrochromatography (CEC) [27], mass spectrometry (MS) [28-29], and 79 
CE [30].  80 
In the last two decades, monolithic columns have proved to be an effective alternative 81 
to packed columns and have attracted considerable interest owing to their facile 82 
preparation methodology and good column characteristics, such as permeability and 83 
efficiency [31-34]. In our recent study [31], the poly(MQD-co-HEMA-co-EDMA)  84 
monolithic column was systemically re-optimized according to Lämmerhofer et al. 85 
[35-36] with some modifications. This column exhibited excellent enantioselectivity 86 
and good efficiency in the micro-LC mode for a wide range of N-derivatized amino 87 
acids [31]. However, the applicability of the poly(MQD-co-HEMA-co-EDMA) 88 
monolith for the stereoselective analysis of small peptides have not been reported so 89 
far.  90 
In the present study, the enantio- and diastereoselective potential of the 91 
poly(MQD-co-HEMA-co-EDMA) monolithic column was systematically evaluated 92 
for the micro-LC separation of a series of N-derivatized di- and tri-peptide 93 













stereoisomers. The influence of the apparent pH of the mobile phase, the organic 94 
solvent content, and the buffer concentration on the chiral separation of di- and 95 
tri-peptide derivatives has also been investigated. Finally, a method based on this 96 
monolithic column was developed and evaluated for the quantitative analysis of the 97 
dipeptide carnosine, labeled as a pure enantiomer (L-carnosine) in several dietary 98 
supplements. 99 
 100 
2. Materials and methods  101 
2.1. Reagents and samples. 102 
All reagents employed were of analytical grade. Acetonitrile (ACN), methanol 103 
(MeOH), acetic acid, and chloroform (CHCl3) were obtained from Scharlau 104 
(Barcelona, Spain). Boric acid and pentane were purchased from Sigma (St. Louis, 105 
MO, USA), while ammonium acetate was from Merck (Darmstadt, Germany). 106 
9-Fluorenylmethoxycarbonyl (FMOC) chloride and triethylamine were obtained from 107 
Fluka (Buchs, Switzerland). Propylene oxide, 3,5-dinitrobenzoyl (3,5-DNB) chloride, 108 
3,5-dichlorobenzoyl (3,5-DClB) chloride, 3,5-dimethoxybenzoyl (3,5-DMB) chloride, 109 
DL-Alanyl-DL-Alanine (DL-Ala-DL-Ala), DL-Alanyl-DL-Leucine 110 
(DL-Ala-DL-Leu), DL-Alanyl-DL-Methionine (DL-Ala-DL-Met), 111 
DL-Alanyl-DL-Valine (DL-Ala-DL-Val), DL-Alanyl-DL-Phenylalanine 112 
(DL-Ala-DL-Phe), DL-Leucyl-DL-Valine (DL-Leu-DL-Val), DL-Leucyl-Glycine 113 
(DL-Leu-Gly), DL-Leucyl-DL-Phenylalanine (DL-Leu-DL-Phe), 114 
DL-Leucyl-Glycyl-Glycine (DL-Leu-Gly-Gly), DL-Leucyl-Glycyl-DL-Phenylalanine 115 
(DL-Leu-Gly-DL-Phe), Glycyl-DL-norLeucine (Gly-DL-norLeu), 116 
Glycyl-DL-norValine (Gly-DL-norVal), and L-carnosine were purchased from Tokyo 117 
Chemical Industry Co., Ltd. (Tokyo, Japan). DL-Leucyl-DL-Alanine 118 













(DL-Leu-DL-Ala) was obtained from Bachem (Switzerland). D-Carnosine was a 119 
generous gift from Flamma S.p.A (Chignolo di’Isola, Bergamo, Italy). Dietary 120 
supplements containing L-carnosine were commercially available and obtained in 121 
several health food shops in Alcalá de Henares, Spain. Distilled water was deionized 122 
using a Milli-Q system (Millipore, Bedford, MA, USA). 123 
2.2.  Apparatus. 124 
A detailed description of the preparation of the poly(MQD-co-HEMA-co-EDMA) 125 
monolithic column for micro-LC by in situ copolymerization of MQD, HEMA, and 126 
EDMA, can be found in an earlier paper [31]. All micro-LC experiments were 127 
performed on a laboratory self-assembled system that consisted of a Shimadzu 128 
LC-10AS pump (Shimadzu, Kyoto, Japan), a UV-Vis detector model 200 (Linear 129 
instruments, Fremont, California, USA), and a Valco four-port injection valve with a 130 
20 nL internal loop (Houston, TX, USA). To reduce the flow and pressure inside the 131 
capillary column, a T-shaped stainless steel piece (Cheminert, Valco Instruments 132 
Houston, Texas, USA) was employed to connect the pump to the injection valve via a 133 
split-flow capillary (dimensions: 150 mm × 25 µm I.D). Data acquisition and data 134 
handling were performed using a N2000 chromatography workstation (Science 135 
Technology, Hangzhou, China). The pH values were measured with a 744 pH-meter 136 
from Metrohm (Herisau, Switzerland).   137 
2.3.  Chromatographic conditions. 138 
Unless otherwise stated, the mobile phase was a mixture of 0.1 M ammonium 139 
acetate/ACN (35/65, v/v). The apparent pH of the mixture was adjusted to the desired 140 
pH with acetic acid. The total flow rate was set to 20 μL/min. The mobile phase for 141 
the separation of FMOC-derivatized peptides was a mixture of ACN/MeOH (35/65, 142 
v/v) containing 0.1 M acetic acid and 4 mM of triethylamine. The separation of 143 













FMOC-derivatized peptides was performed at a total flow rate of 10 μL/min. The 144 
mobile phase was filtered through a 0.22-μm membrane and degassed before use. The 145 
injection volume of all samples was 20 nL and the analytes were all monitored at a 146 
wavelength of 254 nm, using on-column detection.  147 
2.4.  Derivatization of small peptides in standard solutions and dietary 148 
supplements. 149 
Three different L-carnosine dietary supplement products were obtained from health 150 
food shops in Alcalá de Henares, Spain. Sample 1 was a supplement tablet containing 151 
500 mg L-carnosine plus some excipients like cellulose, stearic acid and silica. 152 
Samples 2 and 3 were capsules containing only 500 mg L-carnosine as the active 153 
ingredient. A stock solution of each product was prepared by grinding tablets or the 154 
content of emptied capsules to a fine powder and transferring a certain amount of 155 
powder into a 50 mL conical flask to which 0.2 M borate buffer (pH 9.0) was added. 156 
After weighing the flask, the solution was stirred magnetically for 30 min and 157 
sonicated for 30 min to dissolve L-carnosine completely. After removal of the stir bar, 158 
a slight amount of borate buffer was added into the flask in order to maintain its total 159 
weight constant. The solution was shaken and undissolved ingredients were 160 
removed by centrifugation and filtration. The theoretical L-carnosine concentration of 161 
the solutions was 40 mM, on the basis of the label declarations.  162 
The N-derivatized di- or tri-peptides were synthesized according to the literature [37], 163 
except for the FMOC derivatives. For example, to 0.152 mmol of peptide standard or 164 
dietary supplement suspended in 10 mL of dry CHCl3, 0.167 mmol of 165 
3,5-dinitrobenzoyl chloride and 0.172 mmol of propylene oxide were added. After 166 
sonication for 1 h at room temperature, the solvent was evaporated under nitrogen, the 167 
crude N-(3,5-dinitrobenzoy1) peptide was dissolved in methanol and the solution was 168 













filtered to remove any insoluble residue [37]. As described previously [38-39], 169 
peptides were amidated by 9-fluorenylmethoxycarbonyl chloride in aqueous solution 170 
to afford FMOC derivatives. Briefly, 300 μL of 60 mM FMOC chloride were mixed 171 
with 300 μL of 20 mM peptide standard or dietary supplement solution in 0.2 M 172 
borate buffer (pH 9.0). The reacted mixture was kept at room temperature for 2 min, 173 
and was then extracted with 600 μL of pentane to remove the reagent excess. Finally, 174 
the FMOC-peptide solution was diluted 10 times with mobile phase prior to injection 175 
[38-39].  176 
2.5.  Data treatment and calculations 177 
The resolution (Rs) between adjacent peaks was determined according to the 178 
following equation:  179 
 180 
 181 
where tR1, tR2 are the retention times of the adjacent peaks, respectively, and w1/2,1 and 182 
w1/2,2 are their corresponding widths at half-height [40]. 183 
The enantioselectivity (α) and the theoretical plate number (N) were obtained 184 
according to standard equations from the literature [31,41-42]. Experimental data 185 
analysis was performed using Excel Microsoft 2007 and Origin 7.5. A comparison of 186 
the slopes of regression lines was based on F- and t-tests using Statgraphics Plus 5.0. 187 
 188 
3. Results and Discussion 189 
3.1. Investigation of the enantio- and diastereoselectivity of the 190 
poly(MQD-co-HEMA-co-EDMA) monolithic column toward N-derivatized di- 191 
and tri-peptides  192 




















poly(MQD-co-HEMA-co-EDMA) monolithic column in the micro-LC mode for 194 
N-derivatized di- and tri-peptide stereoisomers, nine N-protected small peptides were 195 
employed as test analytes (DL-Ala-DL-Ala, DL-Ala-DL-Leu, and DL-Leu-DL-Ala, 196 
with three different derivatization agents, 3,5-DNB, 3,5-DClB, and 3,5-DMB 197 
chlorides). The structures of the different N-protecting groups and small peptides 198 
studied in this paper are presented in Fig. S1. The influence of the apparent pH of the 199 
mobile phase, the organic solvent and buffer concentrations were especially 200 
investigated.  201 
The apparent pH is one of the most critical factors in the optimization of the mobile 202 
phase composition. Different apparent pH values were tested (4.0, 5.0, 5.3, and 6.0) in 203 
a mobile phase made of 0.05 M ammonium acetate/ACN (35/65, v/v). As can be seen 204 
in Table S1, the retention factors of the nine N-derivatized dipeptides dramatically 205 
increased as the mobile phase pH increased from 4.0 to 6.0. However, the increase in 206 
retention was somewhat more pronounced for the stereoisomers of the dipeptide 207 
derivatives in positions 1 and 4 in the chromatograms, so that the α1/2 values had a 208 
slight tendency to decrease with increasing pH while the opposite effect was observed 209 
for the α3/4 values (Table S1). Moreover, the stereoisomers of all dipeptide derivatives 210 
could not be completely separated at pH 6.0. The best compromise with respect to 211 
overall selectivity and resolution was obtained at pH 5.3. At this apparent pH, a 212 
baseline separation was observed for the four stereoisomers of 213 
3,5-DNB-DL-Ala-DL-Leu, 3,5-DNB-DL-Leu-DL-Ala, 3,5-DClB-DL-Ala-DL-Leu, 214 
3,5-DClB-DL-Leu-DL-Ala and 3,5-DMB-DL-Leu-DL-Ala. This positive effect might 215 
be attributed to optimum electrostatic interaction between the positively charged 216 
tertiary nitrogen of quinidine on the monolithic CSP and the negatively charged 217 
carboxylate function of the N-derivatized dipeptides at pH 5.3. Furthermore, 218 













according to Lindner et al., the electrostatic interactions would keep the chiral selector 219 
and the analyte close enough, so that other intermolecular interactions, such as 220 
additional stereoselective hydrogen bonding, π-π and steric interactions, could take 221 
place and contribute to the separation of the dipeptide stereoisomers [13,26,43-46]. 222 
Therefore, a mobile phase apparent pH of 5.3 was selected for further experiments.  223 
The organic modifier proportion in the mobile phase is another important parameter in 224 
the optimization of the separation of the stereoisomers of N-derivatized small peptides. 225 
As shown in Table S2, the selectivities remained almost constant while the retention 226 
factors and the resolution values for the stereoisomers of the nine tested analytes 227 
decreased when the ACN content was increased from 55 to 75%. These results 228 
indicated the existence of a hydrophobic retention on the 229 
poly(MQD-co-HEMA-co-EDMA) monolithic stationary phase under these separation 230 
conditions. In order to make a trade-off between resolution and analysis time, a 231 
mobile phase containing 65% ACN was selected for further studies. 232 
The influence of the ammonium acetate concentration in the mobile phase on 233 
retention, selectivity and resolution was also studied by varying the buffer 234 
concentration from 0.05 to 0.15 M, while the other separation conditions were kept 235 
constant (Table S3). No significant influence on selectivity was observed for the 236 
stereoisomers of the nine N-derivatized small peptides over this concentration range, 237 
but their retention factors and resolution values increased with decreasing buffer 238 
concentration. These results seem to indicate that electrostatic interactions contribute 239 
to the retention of the N-derivatized small peptides. Finally, a 0.1 M concentration of 240 
ammonium acetate was chosen as a good compromise between resolution and 241 
analysis time.  242 
Unless otherwise stated, the stereoisomers of the other N-derivatized di- and 243 













tripeptides examined could be separated under the same chromatographic conditions 244 
as those selected for the nine tested dipeptides. In a few cases, better results were 245 
obtained by decreasing the ACN content in the mobile phase from 65 to 50 % or by 246 
replacing ACN with MeOH. For FMOC derivatives, chiral separations could only be 247 
achieved with a polar organic mobile phase consisting of a mixture of ACN and 248 
MeOH (see section 3.2).  249 
As can be seen in Table 1, all stereoisomers of 24 out of the 53 N-derivatized di- and 250 
tripeptides could be baseline separated. In most cases, the stereoisomers of the 251 
N-derivatized di- and tri-peptides could be at least partially separated, except those of 252 
3,5-DMB-DL-Leu-DL-Val, 3,5-DMB-DL-Leu-Gly-DL-Phe, 253 
3,5-DMB-Gly-DL-norVal, 3,5-DMB-Gly-DL-norLeu, FMOC-DL-Ala-DL-Met, 254 
FMOC-DL-Leu-Gly-Gly, FMOC-DL-Leu-Gly-DL-Phe, FMOC-Gly-DL-norLeu and 255 
FMOC-Gly-DL-norVal. Fig. 1 depicts representative chromatograms obtained under 256 
the selected conditions. It is worth noting that the four stereoisomers of the dipeptide 257 
derivatives have not equivalent peak areas: one pair of enantiomers is generally 258 
present in a larger amount than the other one, in accordance with previous 259 
observations [14,21]. It is then easy to see that the resolution of one enantiomeric pair 260 
(peaks in positions 1 and 4) is much higher than that of the other one (peaks in 261 
positions 2 and 3). This also explains why the separation of diastereomers (peaks 1-2 262 
or 3-4) is often more difficult to obtain than enantioseparations. 263 
Table 1 also shows that the highest enantioselectivity and resolution values were 264 
obtained for the stereoisomers of 3,5-DNB derivatives, followed by those of 265 
3,5-DClB derivatives. These results demonstrate that the 266 
poly(MQD-co-HEMA-co-EDMA) monolithic column is well suited to the separation 267 
of the enantiomers and diastereomers of N-derivatized di- and tripeptides.  268 













From these results several other conclusions can be drawn. First, the influence of 269 
N-protecting groups with different levels of π-acidity such as those possessing 270 
aromatic rings with different electron densities can be investigated. As a general 271 
observation, the π-acidity groups have a favorable impact on the chiral separation of 272 
the peptide derivatives. As could be expected, the selectivities for the stereoisomers of 273 
the peptide derivatives were found to decrease with decreasing electrophilic character 274 
of the N-protecting groups (3,5-DNB > 3,5-DClB > 3,5-DMB, cf. Tables S3 and 1). 275 
The higher selectivities obtained for 3,5-DNB derivatives (e.g. α 276 
(3,5-DNB-DL-Ala-DL-Leu) = 1.17, 1.69, 1.40) could be explained by the fact [45] 277 
that the electron-deficient 3,5-DNB group will undergo stronger π-π interaction with 278 
the electron-rich quinoline ring of quinidine than the 3,5-DClB (e.g. α 279 
(3,5-DClB-DL-Ala-DL-Leu) = 1.18, 1.37, 1.20) and 3,5-DMB (e.g. α 280 
(3,5-DMB-DL-Ala-DL-Leu) = 1.20, 1.24, 1.00) groups (Table S3). This additional 281 
chiral discrimination increment could facilitate the separation and lead to an increase 282 
in the resolution of the stereoisomers of N-derivatized peptides [45].  283 
On the other hand, it is clear that the 3,5-DNB derivatives exhibit higher selectivities 284 
than the FMOC derivatives (Table 1). This trend was evidenced by comparison of the 285 
selectivities for a wide range of dipeptide derivatives, including 286 
3,5-DNB-DL-Ala-DL-Leu (α = 1.17, 1.69, 1.40) and FMOC-DL-Ala-DL-Leu (α = 287 
1.18, 1.16, 1.00) (see Table 1). However, 3,5-DNB-, 3,5-DClB- and 288 
3,5-DMB-derivatives of carnosine could not be prepared according to the 289 
derivatization method used for other small peptides due to the low solubility of 290 
carnosine in most organic solvents [47]. Moreover, when carnosine was dissolved in 291 
aqueous solution, the corresponding derivatization agents reacted with water so that 292 
the products could not be obtained, FMOC-carnosine being the only derivative that 293 













we could study.  294 
From the results given in Table 1, another interesting observation can be made: the 295 
effect on chiral recognition when introducing one or two achiral glycine moieties into 296 
an amino acid or a dipeptide. For that purpose, 3,5-DClB protected DL-Leu, 297 
DL-Leu-Gly, DL-Leu-Gly-Gly, DL-Leu-DL-Phe, and DL-Leu-Gly-DL-Phe were 298 
chosen as test analytes under the usual chromatographic conditions (0.1 M ammonium 299 
acetate/ACN (35/65, v/v), apparent pH = 5.3). With the exception of 300 
3,5-DClB-DL-Leu-Gly-DL-Phe, a successful separation was achieved for all pairs of 301 
enantiomers or diastereomers (Table 1). It is interesting to note that the retention 302 
factors, enantioselectivities, and resolution values decrease by addition of glycine 303 
moieties. For instance, the α values for some amino acid or peptide enantiomers or 304 
diastereomers as 3,5-DClB derivatives decrease as follows: DL-Leu (α = 2.95) > 305 
DL-Leu-Gly (α = 1.96) > DL-Leu-Gly-Gly (α = 1.21) in the one hand and 306 
DL-Leu-DL-Phe (α = 1.31, 1.23, 2.04) > DL-Leu-Gly-DL-Phe (α = 1.07, 1.16, 1.00) 307 
on the other hand. This finding is consistent with the conclusions of earlier studies 308 
that the reduction of selectivity may be attributed to a loss of enantiomer or 309 
diastereomer discriminating interactions as a consequence of the increment in the 310 
chain length [26,43-44]. 311 
Finally, in order to confirm the enantiomer elution order, LL-form and DL-form 312 
enantio-enriched 3,5-DNB-Ala-Leu and 3,5-DClB-Leu-Phe were selected as analytes. 313 
As shown in Fig. S2, the LL-form of 3,5-DNB-Ala-Leu was eluted first and followed 314 
with LD-, DL- and DD-form in turns. The same enantiomer elution order was also 315 
observed for 3,5-DClB-DL-Leu-DL-Phe.  316 
3.2. Development of a micro-LC method for the individual quantification of 317 
carnosine enantiomers employing the poly(MQD-co-HEMA-co-EDMA) 318 













monolithic column 319 
The successful separation of the stereoisomers of most N-derivatized di- and 320 
tri-peptides on the poly(MQD-co-HEMA-co-EDMA) monolithic column encouraged 321 
us to apply this chiral discrimination system to the analysis of real samples. In a 322 
previous study, Su et al. developed a sensitive LC method for the simultaneous 323 
determination of carnosine enantiomers in rat plasma [6]. After derivatization with 324 
o-phthaladehyde and N-acetyl-L-cysteine, the carnosine enantiomers were separated 325 
on an ODS column and quantified using fluorescence detection. The lowest limit of 326 
quantification (LLOQ) was 40 ng/mL for each enantiomer [6]. In order to evaluate the 327 
applicability of the poly(MQD-co-HEMA-co-EDMA) monolithic column, a 328 
micro-LC method for the stereoselective determination of L-carnosine in different 329 
dietary supplements was developed. 330 
From initial experiments with a hydro-organic mobile phase (0.1 M ammonium 331 
acetate/ACN (35/65, v/v), apparent pH = 5.3), it became evident that the 332 
FMOC-DL-carnosine enantiomers could not be successfully separated. Therefore, a 333 
polar organic mobile phase consisting of ACN/MeOH (50/50, v/v) containing 0.1 M 334 
acetic acid and 4 mM triethylamine was chosen for method development. First of all, 335 
the effect of the ACN content in the mobile phase was tested in the range from 50 to 336 
20 %. A decrease in the ACN content resulted in an increase in the retention of the 337 
FMOC-DL-carnosine enantiomers (from 12 to 18 min); however, a baseline 338 
separation of these enantiomers could not be achieved in the studied ACN 339 
concentration range and a mobile phase with an intermediate ACN content (35 %) 340 
was chosen. Other parameters such as acetic acid concentration and flow rate were 341 
also investigated. Different concentrations of acetic acid in the mobile phase were 342 
evaluated (0.05, 0.1 and 0.15 M), keeping the ratio of ACN/MeOH constant at 35/65 343 













(v/v). However, the variation of acetic acid concentration did not lead to an important 344 
improvement in the enantioresolution of FMOC-DL-carnosine, so that the 0.1 M 345 
concentration was selected. Finally, the total flow rate was studied in the 10-30 346 
µL/min range. By decreasing the total flow rate, a significant increase in 347 
enantioresolution was obtained. Therefore, using a mobile phase consisting of 348 
ACN/MeOH (35/65, v/v) containing 0.1 M acetic acid and 4 mM triethylamine at a 349 
total flow rate of 10 µL/min, a baseline separation of FMOC-DL-carnosine 350 
enantiomers could be achieved (Fig. 2).  351 
Furthermore, in order to obtain a reliable derivatization method, the conditions 352 
affecting the reaction between DL-carnosine and FMOC chloride, such as the FMOC 353 
chloride/DL-carnosine concentration ratio, the buffer pH and the reaction time were 354 
also investigated. After evaluating the effect of the FMOC chloride/DL-carnosine 355 
concentration ratio on the average peak area, a ratio of 3 was found to be optimum 356 
and selected for further experiments (Fig. S3). The influence of the reaction time was 357 
also studied in the range from 0.5 to 5 min. At times higher than 1 min, the reaction 358 
was found to reach the same yield as that at 5 min; therefore, a reaction time of 2 min 359 
was selected. The next step was to study the effect of the buffer pH employed in the 360 
reaction medium. As this reaction needs a basic medium to take place, the tested pH 361 
values ranged from 8 to 10. The maximum reaction rate was achieved at pH 9.0, this 362 
result being consistent with the findings of a previous study [48]. These results 363 
demonstrate that the developed derivatization method can be used for a quantitative 364 
application. 365 
3.3. Validation of the developed method  366 
Before proceeding with the analysis of L-carnosine in real samples, the analytical 367 
characteristics of the developed method such as selectivity, linearity, precision, 368 













accuracy, LOD, the limit of quantification (LOQ), and the stability of the standard 369 
solution of the FMOC derivative, were studied.  370 
The developed method has proved to be selective for carnosine enantiomers as no 371 
interfering peaks originating from the sample matrices were found; the small peak 372 
observed in all samples at the front of the L-carnosine peak is most probably an 373 
impurity of L-carnosine, also present in trace amounts in the reference standard (Fig. 374 
2). However, the analysis time was fairly long and the peaks were rather broad. This 375 
might be due to the extra-column volume contributions. Concentration ranges for 376 
calibration curves were 0.19-15 mM for L-carnosine and 0.019-1.5 mM for 377 
D-carnosine, respectively. As can be seen in Table 2, linearity was adequate in both 378 
cases since R2 values were > 99.0 %, confidence intervals for the slopes did not 379 
include the zero value and confidence intervals for the intercepts included the zero 380 
value (at a 95 % confidence level). Moreover, the p-value of the t-test between the 381 
standard calibration and standard addition calibration methods allowed to conclude 382 
that no matrix interferences existed since for both enantiomers, this value was above 383 
0.05 (at a 95 % confidence level) (Table 2). Thus, external standard calibration 384 
method has proved to be adequate for the quantification of carnosine enantiomers in 385 
the dietary supplement products.  386 
Method accuracy was evaluated by measuring the recoveries obtained from solutions 387 
of DL-carnosine spiked samples, injected in triplicate, at three different percentages of 388 
the labeled content (80, 100 and 120%). Mean recoveries were acceptable as they 389 
were near 100% (see Table 2). Method precision was evaluated in terms of 390 
instrumental and method repeatabilities, and intermediate precision. RSD values (%) 391 
obtained for areas and retention times are shown in Table 2. It can be concluded that 392 
RSD (%) obtained for peak areas are acceptable as they were < 5 % for instrumental 393 













repeatability and < 10% for method repeatability and intermediate precision. The limit 394 
of detection for D-carnosine was calculated as equivalent to 3 times the S/N ratio, 395 
which corresponds to 6.25 µM, while the limit of quantification was determined as 396 
equivalent to 10 times the S/N ratio, resulting in a value of 20.8 µM (Table 2). It is 397 
worth noting that both LOD and LOQ values for D-carnosine were determined in the 398 
presence of a large excess of L-carnosine (see Figs. 2A and B).  399 
Finally, the stability of FMOC-L-carnosine stored at 4 ºC was evaluated by injecting a 400 
solution containing 2 mM FMOC-L-carnosine in triplicate in three different days. 401 
RSD values were 0.8 and 4.8 % for retention times and peak areas, respectively. 402 
 403 
3.4. Quantification of carnosine in dietary supplements 404 
The developed and validated quantitative method was applied to the analysis of 405 
carnosine enantiomers in dietary supplement products. Three different products, 406 
containing in principle 500 mg of L-carnosine per tablet or capsule, were analyzed. 407 
Table 3 shows the results obtained for the analyzed samples. In all cases, the 408 
concentration of D-carnosine was below the detection limit (see Figs. 2A and 409 
C) of the present method and the amount of L-carnosine was in agreement with the 410 
labeled content for all the analyzed products (Table 3). 411 
4. Conclusions 412 
In this research, the poly(MQD-co-HEMA-co-EDMA) chiral monolithic column has 413 
been evaluated in terms of performance and stereoselectivity towards a wide range of 414 
N-derivatized di- and tri-peptides, using a laboratory self-assembled micro-LC system. 415 
A baseline separation of all stereoisomers of 24 out of the 53 small peptide derivatives 416 
studied was obtained with this CSP, demonstrating its excellent enantioselectivity and 417 
diastereoselectivity. The effects of the apparent pH of the mobile phase, the organic 418 













solvent content and the buffer concentration on the retention and separation of the 419 
stereoisomers of N-derivatized di- and tri-peptides seem to confirm that electrostatic 420 
and hydrophobic interactions are both responsible for the retention of these acidic 421 
analytes while chiral recognition is more related to other kinds of intermolecular 422 
interactions, such as hydrogen binding, π-π and steric interactions. Finally, a method 423 
was developed to quantify carnosine enantiomers in real samples and its analytical 424 
characteristics (linearity, specificity, accuracy, precision, LOD, and LOQ) were 425 
evaluated. The applicability of the validated method has been demonstrated by 426 
analyzing carnosine in several dietary supplements. 427 
 428 
Acknowledgments  429 
We gratefully appreciate the financial support from the National Natural Science 430 
Foundation of China (Grants: 81273477 and 81202499), the Ministry of Economy and 431 
Competitiveness (Spain) (research project CTQ2013-48740-P) and the Comunidad of 432 
Madrid (Spain) and European funding from FEDER program (research project 433 
S2013/ABI-3028, AVANSECAL-CM). Qiqin Wang gratefully acknowledges funding 434 
from “Short-term abroad research program” and “Excellent doctoral climb program” 435 
within Jinan University. Elena Sánchez-López thanks the University of Alcalá for her 436 
pre-doctoral grant. 437 
 438 
References: 439 
[1] J. Liao, I. Lin, K. Huang, P. Kuo, S. Wu, T. Wu, Carnosine ameliorates lens protein turbidity 440 
formations by inhibiting calpain proteolysis and ultraviolet c-induced degradation, J. Agric. Food 441 
Chem. 62 (2014) 5932-5938. 442 
[2] V. Lanza, F. Bellia, R. D’Agata, G. Grasso, E. Rizzarelli, G. Vecchio, New glycoside 443 
derivatives of carnosine and analogs resistant to carnosinase hydrolysis: Synthesis and 444 













characterization of their copper (II) complexes, J. Inorg. Biochem. 105 (2011) 181-188.  445 
[3] A.A. Boldyrev, G. Aldini, W. Derave, Physiology and pathophysiology of carnosine, Physiol. 446 
Rev. 93 (2013) 1803-1845. 447 
[4] R. Kohen, Y. Yamamoto, K.C. Cundy, B.N. Ames, Antioxidant activity of carnosine, 448 
homocarnosine, and anserine present in muscle and brain, Proc. Natl. Acad. Sci. USA 85 (1988) 449 
3175-3179. 450 
[5] G.I. Grasso, F. Bellia, G. Arena, G. Vecchio, E. Rizzarelli, Noncovalent interaction-driven 451 
stereoselectivity of copper (II) complexes with cyclodextrin derivatives of L- and D-carnosine, 452 
Inorg. Chem. 50 (2011) 4917-4924. 453 
[6] D. Su, K. Bi, C. Zhou, Y. Song, B. Wei, L. Geng, W. Liu, X. Chen, Enantioselective separation 454 
and determination of carnosine in rat plasma by fluorescence LC for stereoselective 455 
pharmacokinetic studies, Chromatographia 71 (2010) 603-608.  456 
[7] B. Sungthong, R. Iványi, S.C. Bunz, C. Neusüß, G.K.E. Scriba, CE-MS characterization of 457 
negatively charged α-, β- and γ-CD derivatives and their application to the separation of dipeptide 458 
and tripeptide enantiomers by CE, Electrophoresis 31 (2010) 1498-1505.  459 
[8] I. Ali, Z.A. Al-Othman, A. Al-Warthan, L. Asnin, A. Chudinov, Advances in chiral separations 460 
of small peptides by capillary electrophoresis and chromatography, J. Sep. Sci. 37 (2014) 461 
2447-2466. 462 
[9] R. Ludewig, S. Nietzsche, G.K.E. Scriba, A weak cation-exchange monolith as stationary 463 
phase for the separation of peptide diastereomers by CEC, J. Sep. Sci. 34 (2011) 64-69. 464 
[10] G.K.E. Scriba, Recent developments in peptide stereoisomer separations by capillary 465 
electromigration techniques, Electrophoresis 30 (2009) S222-S228. 466 
[11] C. Czerwenka, W. Lindner, Stereoselective peptide analysis, Anal. Bioanal. Chem. 382 (2005) 467 
599-638.    468 
[12] V. Kašička, Recent developments in capillary and microchip electroseparations of peptides 469 
(2011-2013), Electrophoresis 35 (2014) 69-95. 470 
[13] C. Czerwenka, N.M. Maier, W. Lindner, Liquid chromatographic-mass spectrometric 471 
separation of oligoalanine peptide stereoisomers: influence of absolute configuration on 472 
enantioselectivity and two-dimensional separation of diastereomers and enantiomers, J. 473 













Chromatogr. A 1038 (2004) 85-95. 474 
[14] C. Czerwenka, M. Lämmerhofer, W. Lindner, Micro-HPLC and standard-size HPLC for the 475 
separation of peptide stereoisomers employing an ion-exchange principle, J. Pharm. Biomed. Anal. 476 
30 (2003) 1789-1800. 477 
[15] U. Conrad, B. Chankvetadze, G.K.E. Scriba, High performance liquid chromatographic 478 
separation of dipeptide and tripeptide enantiomers using a chiral crown ether stationary phase, J. 479 
Sep. Sci. 28 (2005) 2275-2281. 480 
[16] B. Esquivel, L. Nicholson, L. Peerey, Enantiomeric resolution of underivatized small peptides 481 
by HPLC with a chiral crown ether stationary phase, JJ. High Resolut. Chromatogr. 14 (1991) 482 
816-823. 483 
[17] M. Hilton, D.W. Armstrong, Evaluation of the enantiomeric separation of dipeptides using a 484 
chiral crown ether LC column, J. Liq. Chromatogr. 14 (1991) 3673-3683. 485 
[18] M.G. Schmid, M. Hölbling, N. Schnedlitz, G. Gübitz, Enantioseparation of dipeptides and 486 
tripeptides by micro-HPLC comparing teicoplanin and teicoplanin aglycone as chiral selectors, J. 487 
Biochem. Biophys. Methods 61 (2004) 1-10. 488 
[19] A. Berthod, Y. Liu, C. Bagwill, D.W. Armstrong, Facile liquid chromatographic 489 
enantioresolution of native amino acids and peptides using a teicoplanin chiral stationary phase, J. 490 
Chromatogr. A 731 (1996) 123-137. 491 
[20] S. Chen, The HPLC resolution of N-2,4-dinitrophenylated amino acids and peptides 492 
stereoisomers on naphthylethylcarbamate-β-cyclodextrin bonded phase using the 493 
acetonitrile-based mobile phase: evidence for the chiral recognition pattern, Amino acids 27 (2004) 494 
277-284. 495 
[21] S. Chen, The facile HPLC enantioresolution of amino acids, peptides on 496 
naphthylethylcarbamate-β-cyclodextrin bonded phases using the acetonitrile-based mobile phase 497 
after their pre-column derivatization with phenyl isothiocyanate: factors that affect the resolution, 498 
Amino acids 26 (2004) 291-298. 499 
[22] S. Schiesel, M. Lämmerhofer, A. Leitner, W. Lindner, Quantitative high-performance liquid 500 
chromatography-tandem mass spectrometry impurity profiling methods for the analysis of 501 
parenteral infusion solutions for amino acid supplementation containing L-alanyl-L-glutamine, J. 502 













Chromatogr. A 1259 (2012) 111-120. 503 
[23] S. Wernisch, O. Trapp, W. Lindner, Application of cinchona-sulfonate-based chiral 504 
zwitterionic ion exchangers for the separation of proline-containing dipeptide rotamers and 505 
determination of on-column isomerization parameters from dynamic elution profiles, Anal. Chim. 506 
Acta. 795 (2013) 88-98. 507 
[24] S. Wernisch, W. Lindner, Versatility of cinchona-based zwitterionic chiral stationary phases: 508 
Enantiomer and diastereomer separations of non-protected oligopeptides utilizing a multi-modal 509 
chiral recognition mechanism, J. Chromatogr. A 1269 (2012) 297-307. 510 
[25] A. Mucha, M. Lämmerhofer, W. Lindner, M. Pawelczak, P. Kafarski, Individual 511 
stereoisomers of phosphinic dipeptide inhibitor of leucine aminopeptidase, Bioorg. Med. Chem. 512 
Lett. 18 (2008) 1550-1554. 513 
[26] C. Czerwenka,  P. Polásková,  W. Lindner, Peptide enantiomer separations: Influence of 514 
sequential isomerism and the introduction of achiral glycine moieties on chiral recognition, J. 515 
Chromatogr. A 1093 (2005) 81-88. 516 
[27] B. Preinerstorfer, D. Lubda, A. Mucha, P. Kafarski, W. Lindner, M. Lämmerhofer, 517 
Stereoselective separations of chiral phosphinic acid pseudodipeptides by CEC using silica 518 
monoliths modified with an anion-exchange-type chiral selector, Electrophoresis 27 (2006) 519 
4312-4320. 520 
[28] J.M. Bobbitt, L. Li, D.D. Carlton Jr., M. Yasin, S. Bhawal,  F.W. Foss Jr.,  S. Wernisch, R. 521 
Pell, W. Lindner, K.A. Schug, Diastereoselective discrimination of lysine-alanine-alanine peptides 522 
by zwitterionic cinchona alkaloid-based chiral selectors using electrospray ionization mass 523 
spectrometry, J. Chromatogr. A 1269 (2012) 308-315. 524 
[29] C. Czerwenka, W. Lindner, Enantiomer discrimination of peptides by tandem mass 525 
spectrometry: influence of the peptide sequence on chiral recognition, Rapid Commun. Mass 526 
Spectrom. 18 (2004) 2713-2718. 527 
[30] C. Czerwenka, M. Lämmerhofer, W. Lindner, Electrolyte and additive effects on enantiomer 528 
separation of peptides by nonaqueous ion-pair capillary electrophoresis using 529 
tert.-butylcarbamoylquinine as chiral counterion, Electrophoresis 23 (2002) 1887-1899. 530 
[31] Q. Wang, J. Feng, H. Han, P. Zhu, H. Wu, M.L. Marina, J. Crommen, Z. Jiang, 531 













Enantioseparation of N-derivatized amino acids by micro-liquid chromatography using 532 
carbamoylated quinidine functionalized monolithic stationary phase, J. Chromatogr. A 1363 (2014) 533 
207-215.  534 
[32] Z. Jiang, N.W. Smith, P.D. Ferguson, M.R. Taylor, Hydrophilic interaction chromatography 535 
using methacrylate-based monolithic capillary column for the separation of polar analytes, Anal. 536 
Chem. 79 (2007) 1243-1250.  537 
[33] H. Minakuchi, K. Nakanishi, N. Soga, N. Ishizuka, N. Tanaka, Octadecylsilylated porous 538 
silica rods as separation media for reversed-phase liquid chromatography, Anal. Chem. 68 (1996) 539 
3498-3501. 540 
[34] F. Svec, Porous polymer monoliths: Amazingly wide variety of techniques enabling their 541 
preparation, J. Chromatogr. A 1217 (2010) 902-924. 542 
[35] M. Lämmerhofer,  E.C. Peters,  C. Yu,  F. Svec,  J.M.J. Fréchet, Chiral monolithic columns 543 
for enantioselective capillary electrochromatography prepared by copolymerization of a monomer 544 
with quinidine functionality. 1. Optimization of polymerization conditions, porous properties, and 545 
chemistry of the stationary phase, Anal. Chem. 72 (2000) 4614-4622. 546 
[36] M. Lämmerhofer, F. Svec, J.M.J. Fréchet, Chiral monolithic columns for enantioselective 547 
capillary electrochromatography prepared by copolymerization of a monomer with quinidine 548 
functionality. 2. Effect of chromatographic conditions on the chiral separations, Anal. Chem. 72 549 
(2000) 4623-4628. 550 
[37] W.H. Pirkle, T.C. Pochapsky, Chiral molecular recognition in small bimolecular systems: A 551 
spectroscopic investigation into the nature of diastereomeric complexes, J. Am. Chem. Soc. 109 552 
(1987) 5975-5982.  553 
[38] H. Wan, P.E. Andersson, A. Engström, L.G. Blomberg, Direct and indirect chiral separation of 554 
amino acids by capillary electrophoresis, J. Chromatogr. A 704 (1995) 179-193.  555 
[39] E. Domínguez-Vega, A.L. Crego, K. Lomsadze, B. Chankvetadze, M.L. Marina, 556 
Enantiomeric separation of FMOC-amino acids by nano-LC and CEC using a new chiral 557 
stationary phase, cellulose tris(3-chloro-4-methylphenylcarbamate), Electrophoresis 32 (2011) 558 
2700-2707. 559 
[40] E. Domínguez-Vega, A.B. Martínez-Girón, C. García-Ruiz, A.L. Crego, M.L. Marina, Fast 560 













derivatization of the non-protein amino acid ornithine with FITC using an ultrasound probe prior 561 
to enantiomeric determination in food supplements by EKC, Electrophoresis 30 (2009) 562 
1037-1045. 563 
[41] Q. Zhang, J. Guo, F. Wang, J. Crommen, Z. Jiang, Preparation of a β-cyclodextrin 564 
functionalized monolith via a novel and simple one-pot approach and application to 565 
enantioseparations, J. Chromatogr. A 1325 (2014) 147-154.   566 
[42] V. Piette, M. Lämmerhofer, W. Lindner, J. Crommen, Enantiomer separation of N-protected 567 
amino acids by non-aqueous capillary electrophoresis and high-performance liquid 568 
chromatography with tert.-butyl carbamoylated quinine in either the background electrolyte or the 569 
stationary phase, J. Chromatogr. A 987 (2003) 421-427.  570 
[43] C. Czerwenka, M. Lämmerhofer, N.M. Maier, K. Rissanen, W. Lindner, Direct 571 
high-performance liquid chromatographic separation of peptide enantiomers: Study on chiral 572 
recognition by systematic evaluation of the influence of structural features of the chiral selectors 573 
on enantioselectivity, Anal. Chem. 74 (2002) 5658-5666. 574 
[44] C. Czerwenka, M. Zhang, H. Kählig, N.M. Maier, K.B. Lipkowitz, W. Lindner, Chiral 575 
recognition of peptide enantiomers by cinchona alkaloid derived chiral selectors: Mechanistic 576 
investigations by liquid chromatography, NMR spectroscopy, and molecular modeling, J. Org. 577 
Chem. 68 (2003) 8315-8327. 578 
[45] C. Czerwenka, M. Lämmerhofer, W. Lindner, Structure-enantioselectivity relationships for 579 
the study of chiral recognition in peptide enantiomer separation on cinchona alkaloid-based chiral 580 
stationary phases by HPLC: Influence of the N-terminal protecting group, J. Sep. Sci. 26 (2003) 581 
1499-1508. 582 
[46] C. Czerwenka, N.M. Maier, W. Lindner, Enantiomer discrimination by mass spectrometry: 583 
noncovalent interactions of an N-derivatized dipeptide with various cinchona alkaloid derivatives 584 
and comparison with enantioselective liquid-phase separations, Anal. Bioanal. Chem. 379 (2004) 585 
1039-1044. 586 
[47] E. Husson, C. Humeau, C. Harscoat, X. Framboisier, C. Paris, E. Dubreucq, I. Marc, I. 587 
Chevalot, Enzymatic acylation of the polar dipeptide, carnosine: Reaction performances in organic 588 
and aqueous media, Process Biochem. 46 (2011) 945-952. 589 













[48] A. Jámbor,  I. Molnár-Perl, Quantitation of amino acids in plasma by high performance 590 
liquid chromatography: Simultaneous deproteinization and derivatization with 591 
9-fluorenylmethyloxycarbonyl chloride, J. Chromatogr. A 1216 (2009) 6218-6223.592 














Figure captions 594 
Fig. 1. Separation of N-derivatized small peptide stereoisomers on the poly(MQD-co-HEMA-co-EDMA) 595 
monolithic column. Separation conditions: column dimensions: 210 mm × 100 μm I.D.; mobile phase: (a). 0.1 M 596 
ammonium acetate/ACN (35/65, v/v) (apparent pH = 5.3) for all chromatograms except f, total flow rate: 20 597 
μL/min, backpressure: 24 bar; (b). ACN/MeOH (35/65, v/v), 0.1 M acetic acid, 4 mM triethylamine (apparent pH 598 
= 6.0) for chromatogram f, total flow rate: 5 μL/min, backpressure: 6 bar; UV detection wavelength: 254 nm; 599 
injection volume: 20 nL. 600 
 601 
Fig. 2. A. Chromatogram of D-carnosine at a concentration (6.25 µM) corresponding to LOD in the 602 
presence of a large excess of L-carnosine (0.25 mM). 603 
B. Chromatogram of D-carnosine at a concentration (20.8 µM) corresponding to LOQ in the presence of a 604 
large excess of L-carnosine (0.25 mM).  605 
C.Chromatograms of 1) FMOC-D,L-carnosine standard solution (concentration 1 mM); 2) dietary product 606 
#3; 3) dietary product #2; 4) dietary product #1.  607 
Separation conditions: column dimensions: 210 mm × 100 μm I.D.; mobile phase: ACN/MeOH (35/65, v/v), 0.1 608 
M acetic acid, 4 mM triethylamine (apparent pH = 6.0), total flow rate: 10 μL/min, backpressure: 10 bar; UV 609 
detection wavelength: 254 nm; injection volume: 20 nL. 610 
 611 
Table 1. Retention and separation of N-derivatized peptide stereoisomers on the 612 
poly(MQD-co-HEMA-co-EDMA) monolithic column. Separation conditions: mobile phase, a 0.1 M ammonium 613 
acetate/ACN (35/65, v/v) (apparent pH = 5.3), total flow rate: 20 μL/min; backpressure: 24 bar; b 0.1 M 614 
ammonium acetate/ACN (50/50, v/v) (apparent pH = 5.3), total flow rate: 10 μL/min; backpressure: 20 bar; c 0.1 M 615 
ammonium acetate/MeOH (35/65, v/v) (apparent pH = 5.3), total flow rate: 10 μL/min; backpressure: 16 bar; d 616 
ACN/MeOH (35/65, v/v), 0.1 M acetic acid, 4 mM triethylamine (apparent pH = 6.0), total flow rate: 10 μL/min; 617 
backpressure: 10 bar; e ACN/MeOH (35/65, v/v), 0.1 M acetic acid, 4 mM triethylamine (apparent pH = 6.0), total 618 
flow rate: 5 μL/min; backpressure: 6 bar; UV detection wavelength: 254 nm; injection volume: 20 nL. 619 
 620 
 621 
Table 2. Analytical characteristics of the developed micro-LC method for the individual determination of 622 
carnosine enantiomers in dietary supplements. 623 
a) Six standard solutions at different concentration levels injected in triplicate. 624 
b) Addition of four known amounts of D- and L-carnosine to a dietary supplement sample containing a 625 













constant concentration of L-carnosine. 626 
c) Accuracy was evaluated as the recovery obtained from three dietary supplement sample solutions spiked 627 
with standard D,L-carnosine solution at three different percentages (80, 100, and 120 %) of the labelled 628 
content (n = 9). 629 
d) Six consecutive injections of a dietary supplement sample solution containing 2 mM L-carnosine (as 630 
labeled amount) spiked with 0.5 mM L- and D-carnosine (n = 6). 631 
e) Six dietary supplement sample solutions containing 2 mM L-carnosine (as labeled amount) spiked with 632 
0.5 mM L- and D-carnosine (n = 6).   633 
f) Three dietary supplement sample solutions containing 2 mM L-carnosine (as labeled amount) spiked 634 
with 0.5 mM L- and D-carnosine in 3 different days (n = 9). 635 
g) LOD: equivalent to 3 × S/N. 636 
h) LOQ: equivalent to 10 × S/N. 637 
 638 
Table 3. Analysis of three different dietary supplement products with a labeled content of 500 mg of 639 
L-carnosine per tablet or capsule. ND: Not detected (<LOD). Experimental conditions as in Fig. 2. 640 
 641 
 642 
Table 1. Retention and separation of N-derivatized peptide stereoisomers on the 643 
poly(MQD-co-HEMA-co-EDMA) monolithic column. 644 
Sample k1 k2 k3 k4 α1/2 α2/3 α3/4 Rs 1/2 Rs 2/3 Rs 3/4 N1 
3,5-DNB-DL-Ala-DL-Alaa 2.03 2.26 4.86 5.15 1.12 2.15 1.06 1.16  7.10  0.52 18336 
3,5-DNB-DL-Ala-DL-Leua 1.76 2.05 3.46 4.86 1.17 1.69 1.40 1.55  5.40  3.59 18168 
3,5-DNB-DL-Ala-DL-Vala 1.97 2.41 3.96 4.97 1.23 1.64 1.26 2.04  5.13  2.39 16208 
3,5-DNB-DL-Ala-DL-Meta 1.50 1.50 2.55 2.55 1.00 1.69 1.00 0.00  4.49  0.00 14467 
3,5-DNB-DL-Ala-DL-Pheb 4.72 5.19 7.72 15.44 1.10 1.49 2.00 1.38  6.35  12.33 21294 
3,5-DNB-DL-Leu-DL-Alaa 1.85 2.14 5.00 6.58 1.16 2.34 1.32 1.50  8.95  3.12 19315 
3,5-DNB-DL-Leu-DL-Vala 2.03 2.03 3.38 3.38 1.00 1.67 1.00 0.00  4.32  0.00 12000 
3,5-DNB-DL-Leu-DL-Phea 2.61 3.12 4.91 12.35 1.20 1.57 2.52 1.63  4.06  7.91 13696 
3,5-DNB-DL-Leu-Glya 1.93 4.96   2.57   7.98    13248 
3,5-DNB-DL-Leu-Gly-Glya 1.49 1.96   1.32   2.14    13425 
3,5-DNB-DL-Leu-Gly-DL-Phea 2.01 2.01 2.50 2.74 1.00 1.24 1.09 0.00  1.24  0.59 4439 
3,5-DNB-Gly-DL-norLeua 3.20 4.20   1.31   2.44    11783 
3,5-DNB-Gly-DL-norVala 2.91 3.79   1.30   2.93    16301 
            
3,5-DClB-DL-Ala-DL-Alaa 2.16 2.43 3.96 3.96 1.12 1.63 1.00 1.27  3.94  0.00 20127 
3,5-DClB-DL-Ala-DL-Leua 1.75 2.06 2.83 3.39 1.18 1.37 1.20 1.68  3.38  1.92 19290 
3,5-DClB-DL-Ala-DL-Vala 2.48 2.48 3.25 3.25 1.00 1.31 1.00 0.00  2.68  0.00 15440 
3,5-DClB-DL-Ala-DL-Meta 1.81 1.81 2.50 2.50 1.00 1.38 1.00 0.00  2.93  0.00 14901 
3,5-DClB-DL-Ala-DL-Phea 2.92 3.41 4.17 5.99 1.17 1.22 1.44 1.68  2.10  3.79 15153 
3,5-DClB-DL-Leu-DL-Alaa 1.91 2.24 3.81 4.79 1.18 1.70 1.25 1.52  5.35  2.23 15182 
3,5-DClB-DL-Leu-DL-Vala 2.22 2.22 2.87 2.87 1.00 1.29 1.00 0.00  1.34  0.00 2429 
3,5-DClB-DL-Leu-DL-Phea 2.60 3.42 4.20 8.56 1.31 1.23 2.04 2.53  2.04  6.68 11381 













3,5-DClB-DL-Leu-Glya 2.05 4.02   1.96   6.50    14840 
3,5-DClB-DL-Leu-Gly-Glya 1.45 1.75   1.21   1.70    16183 
3,5-DClB-DL-Leu-Gly-DL-Phea 1.89 2.02 2.35 2.35 1.07 1.16 1.00 0.29  0.80  0.00 2519 
3,5-DClB-Gly-DL-norLeua 3.18 3.68   1.16   1.71    17742 
3,5-DClB-Gly-DL-norVala 3.03 3.47   1.14   1.59    18315 
3,5-DClB-Leucinea 2.57 7.57   2.95   8.71     
    
            
Sample k1 k2 k3 k4 α1/2 α2/3 α3/4 Rs 1/2 Rs 2/3 Rs 3/4 N1 
3,5-DMB-DL-Ala-DL-Alaa 1.28 1.42 1.87 2.00 1.11 1.32 1.07 0.97  2.41  0.51 22949 
3,5-DMB-DL-Ala-DL-Leuc 2.89 3.51 4.57 5.67 1.22 1.30 1.24 1.94  2.68  2.22 13784 
3,5-DMB-DL-Ala-DL-Vala 1.41 1.41 1.68 1.68 1.00 1.19 1.00 0.00  1.37  0.00 12493 
3,5-DMB-DL-Ala-DL-Meta 1.49 1.49 1.94 1.94 1.00 1.30 1.00 0.00  2.22  0.00 13401 
3,5-DMB-DL-Ala-DL-Pheb 2.29 2.66 3.07 3.86 1.16 1.16 1.26 1.89  1.92  3.12 26371 
3,5-DMB-DL-Leu-DL-Alab 1.41 1.65 2.50 3.03 1.18 1.51 1.21 1.77  4.99  2.49 23756 
3,5-DMB-DL-Leu-DL-Vala 1.33 1.33 1.33 1.33 1.00 1.00 1.00 0.00  0.00  0.00 3398 
3,5-DMB-DL-Leu-DL-Pheb 2.96 3.66 4.08 7.48 1.24 1.11 1.83 2.74  1.50  8.35 20081 
3,5-DMB-DL-Leu-Glyb 1.56 2.63   1.69   6.18    23578 
3,5-DMB-DL-Leu-Gly-Glyb 0.84 0.99   1.17   1.34    23237 
3,5-DMB-DL-Leu-Gly-DL-Phea 1.37 1.37 1.37 1.37 1.00 1.00 1.00 0.00  0.00  0.00 16662 
3,5-DMB-Gly-DL-norLeua 1.31 1.31   1.00   0.00    21807 
3,5-DMB-Gly-DL-norVala 1.30 1.30   1.00   0.00    24991 
            
FMOC-DL-Ala-DL-Alad 3.06 3.59 3.79 4.18 1.17 1.06 1.10 1.63  0.57  1.09 15935 
FMOC-DL-Ala-DL-Leud 2.02 2.38 2.77 2.77 1.18 1.16 1.00 1.49  1.40  0.00 13579 
FMOC-DL-Ala-DL-Vald 3.14 3.14 3.58 3.58 1.00 1.14 1.00 0.00  1.02  0.00 8901 
FMOC-DL-Ala-DL-Metd 4.74 4.74 4.74 4.74 1.00 1.00 1.00 0.00  0.00  0.00 9119 
FMOC-DL-Ala-DL-Phed 4.75 5.29 6.00 6.51 1.11 1.13 1.08 1.25  1.44  0.95 15297 
FMOC-DL-Leu-DL-Alad 1.88 2.23 2.44 2.44 1.19 1.09 1.00 1.55  0.80  0.00 14367 
FMOC-DL-Leu-DL-Vald 2.38 2.38 3.64 3.64 1.00 1.53 1.00 0.00  3.04  0.00 6749 
FMOC-DL-Leu-DL-Phee 2.59 2.94 3.81 4.69 1.14 1.29 1.23 1.57  3.25  2.74 19382 
FMOC-DL-Leu-Glye 2.91 3.28   1.13   1.57    24751 
FMOC-DL-Leu-Gly-Glyd 3.24 3.24   1.00   0.00    14842 
FMOC-DL-Leu-Gly-DL-Phed 3.01 3.01 3.01 3.01 1.00 1.00 1.00 0.00  0.00  0.00 2241 
FMOC-Gly-DL-norLeud 3.13 3.13   1.00   0.00    4713 
FMOC-Gly-DL-norVald 3.33 3.33   1.00   0.00    4813 
FMOC-DL-Carnosined 6.87 8.31     1.21     1.55      6339 
 645 
 646 
Separation conditions: mobile phase, a 0.1 M ammonium acetate/ACN (35/65, v/v) (apparent pH = 5.3), total flow 647 
rate: 20 μL/min; backpressure: 24 bar; b 0.1 M ammonium acetate/ACN (50/50, v/v) (apparent pH = 5.3), total 648 
flow rate: 10 μL/min; backpressure: 20 bar; c 0.1 M ammonium acetate/MeOH (35/65, v/v) (apparent pH = 5.3), 649 
total flow rate: 10 μL/min; backpressure: 16 bar; d ACN/MeOH (35/65, v/v), 0.1 M acetic acid, 4 mM 650 
triethylamine (apparent pH = 6.0), total flow rate: 10 μL/min; backpressure: 10 bar; e ACN/MeOH (35/65, v/v), 0.1 651 
M acetic acid, 4 mM triethylamine (apparent pH = 6.0), total flow rate: 5 μL/min; backpressure: 6 bar; UV 652 
detection wavelength: 254 nm; injection volume: 20 nL. 653 
 654 
Table 2. Analytical characteristics of the developed micro-LC method for the 655 













individual determination of carnosine enantiomers in dietary supplements 656 
 L-carnosine D-carnosine 
 
External standard calibration method a) 
  
Range 0.1875 – 15 mM 0.01875 – 1.5 mM 
Slope ± t·sslope 152000 ± 13000 210000 ± 20000 
Intercept ± t·sintercept -13000 ± 101000 2000 ± 17000 
R2 99.8 % 99.5 % 
   
Standard addition calibration method b) 
 
  
Study of matrix interferences (p-value of t-test) 0.162 0.663 
   
Accuracy c) 
 





105 ± 13 
 
 
108 ± 7 
   
   
Instrumental repeatability d)   
t, RSD (%) 0.8 1.8 




t,RSD (%) 0.7 1.5 




t, RSD (%) 2.4 5.0 
A, RSD (%) 7.2 7.8 
  
LOD g) 6.25 µM 6.25 µM 
LOQ h) 20.8 µM 20.8 µM 
 657 
i) Six standard solutions at different concentration levels injected in triplicate. 658 
j) Addition of four known amounts of D- and L-carnosine to a dietary supplement sample 659 
containing a constant concentration of L-carnosine. 660 
k) Accuracy was evaluated as the recovery obtained from three dietary supplement sample 661 
solutions spiked with standard D,L-carnosine solution at three different percentages (80, 100, 662 
and 120 %) of the labelled content (n = 9). 663 
l) Six consecutive injections of a dietary supplement sample solution containing 2 mM 664 
L-carnosine (as labeled amount) spiked with 0.5 mM L- and D-carnosine (n = 6). 665 
m) Six dietary supplement sample solutions containing 2 mM L-carnosine (as labeled amount) 666 
spiked with 0.5 mM L- and D-carnosine (n = 6).   667 
n) Three dietary supplement sample solutions containing 2 mM L-carnosine (as labeled amount) 668 
spiked with 0.5 mM L- and D-carnosine in 3 different days (n = 9). 669 
o) LOD: equivalent to 3 × S/N. 670 
p) LOQ: equivalent to 10 × S/N. 671 
 672 
 673 













Table 3. Analysis of three different dietary supplement products with a labeled content 674 







#1 ND 525 ± 9 105 ± 2 
#2 ND 509 ± 38 102 ± 8 
#3 ND 529 ± 27 106 ± 5 







♦ N-derivatized peptides were successfully enantioresolved on the 683 
poly(MQD-co-HEMA-co-EDMA) monolithic column. 684 
♦ The monolith exhibited good enantioselectivity and diastereoselectivity for 685 
N-derivatized di- and tri- peptides. 686 
♦ The monolith shows potential as a reliable tool for the quality control of 687 
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